ANI director plans 1,000-share stock sale

Director Jeanne Thoma filed a Rule 144 notice to potentially sell 1,000 ANIP common shares valued at about $71,460.

Available on EDGAR 09/11/2026 - 04:35 PM EDT Accepted by SEC EDGAR 09/11/2026 - 04:33 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

ANI PHARMACEUTICALS INC (ANIP) has a notice of proposed sale under Rule 144 filed for the account of director Jeanne Thoma. The filing covers the potential sale of 1,000 shares of common stock through Morgan Stanley Smith Barney LLC on or about September 11, 2026, with an indicated aggregate market value of $71,460. The shares to be sold were acquired as Restricted Stock Awards from the issuer on May 22, 2026; shares of common stock outstanding were stated as 22,959,488 for context.

Key Figures

Shares to be sold: 1,000 shares Aggregate market value: $71,460.00 Shares outstanding: 22,959,488 shares +2 more

5 metrics

Shares to be sold 1,000 shares Common stock covered by the Rule 144 notice for Jeanne Thoma

Aggregate market value $71,460.00 Indicated value of the 1,000 ANIP shares proposed to be sold

Shares outstanding 22,959,488 shares ANI Pharmaceuticals, Inc. common stock outstanding, given as context

Acquisition date of shares May 22, 2026 Date the 1,000 shares were acquired as Restricted Stock Awards

Proposed sale date September 11, 2026 Planned date of sale for the 1,000 ANIP shares on NASDAQ

Key Terms

Rule 144, Restricted Stock Awards, aggregate market value

3 terms

Rule 144 regulatory

"See the definition of "person" in paragraph (a) of Rule 144."

Rule 144 is a U.S. securities regulation that sets conditions under which restricted or insider-held shares can be legally resold to the public, such as required holding periods, availability of public information, limits on how much can be sold at once, and certain filing requirements. For investors it matters because it determines when previously locked-up shares can enter the market — like a release valve that can increase supply, affect share price, and signal insider intent.

Restricted Stock Awards financial

"Common | 05/22/2026 | Restricted Stock Awards | Issuer"

Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.

aggregate market value financial

"Common | Morgan Stanley Smith Barney LLC ... | 1000 | 71460.00"

Aggregate market value is the combined price you would pay to buy all outstanding shares of a company or all companies in a group at current market prices — essentially the sum of each stock’s market capitalization. It matters to investors because it shows the overall size and weight of an investment or sector (like the total cost to buy every piece of a puzzle), helps compare scale across companies or markets, and influences index composition and risk exposure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 filing disclose for ANIP?

It discloses that director Jeanne Thoma has filed a notice under Rule 144 to potentially sell 1,000 shares of ANI Pharmaceuticals, Inc. common stock through Morgan Stanley Smith Barney LLC, with an indicated aggregate market value of $71,460 as of the planned sale date.

How many ANIP shares are covered by Jeanne Thoma’s Form 144 notice?

The notice covers a proposed sale of 1,000 shares of ANI Pharmaceuticals, Inc. common stock. These shares are planned to be sold through Morgan Stanley Smith Barney LLC under Rule 144.

What is the approximate market value of the ANIP shares in this Form 144?

The filing indicates an aggregate market value of $71,460.00 for the 1,000 shares of ANI Pharmaceuticals, Inc. common stock proposed to be sold under Rule 144.

When were the ANIP shares to be sold under this Form 144 acquired?

The shares were acquired on May 22, 2026 as Restricted Stock Awards from ANI Pharmaceuticals, Inc., according to the securities-to-be-sold section of the Form 144 notice.

When is the proposed sale date for the ANIP shares in this Form 144?

The proposed sale date listed is September 11, 2026 for the sale of 1,000 shares of ANI Pharmaceuticals, Inc. common stock on the NASDAQ market.

How many ANIP shares were stated as outstanding in the Form 144?

The Form 144 states that there were 22,959,488 shares of ANI Pharmaceuticals, Inc. common stock outstanding, given as context for the 1,000-share proposed sale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001819879
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	ANI PHARMACEUTICALS, INC
SEC File Number	001-31812
Address of Issuer	104 Carnegie Center Drive, Suite 300 Princeton NEW JERSEY 08540
Phone	(609)759-1810
Name of Person for Whose Account the Securities are To Be Sold	JEANNE THOMA
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Morgan Stanley Smith Barney LLC Executive Financial Services 1 New York Plaza 8th Floor New York NY 10004	1000	71460.00	22959488	09/11/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	05/22/2026	Restricted Stock Awards	Issuer			1000	05/22/2026	N/A

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Nothing to Report

144: Remarks and Signature

Remarks
Date of Notice	09/11/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	06/12/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	/s/ Jeanne Thoma
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)